# Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics

> **NCT03365648** · NA · COMPLETED · sponsor: **NTC srl** · enrollment: 150 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis

## Interventions

- **DIETARY_SUPPLEMENT:** Lertal® + standard therapy
- **OTHER:** Placebo + standard therapy

## Key facts

- **NCT ID:** NCT03365648
- **Lead sponsor:** NTC srl
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-15
- **Primary completion:** 2018-07-04
- **Final completion:** 2018-11-13
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2018-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03365648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03365648, "Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03365648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*